Shaperon, a clinical stage biotech company, has secured $4.6 million in its latest funding round. The company specializes in developing novel inflammasome inhibitors, small molecules designed to suppress a broad spectrum of inflammatory cytokines. Its unique mechanism of action involves GPCR-regulated P2X7 inhibition, which controls both the priming and activation phases of inflammasome, a distinction from conventional approaches that typically target only the activation phase.
This innovative modality is applied to address complex immune-mediated inflammatory disorders. Shaperon is currently advancing multiple clinical programs, including treatments for atopic dermatitis, cytokine release syndrome, Alzheimer’s disease, ulcerative colitis, and NASH. Beyond its inflammasome R&D, Shaperon also develops anti-viral and anti-cancer nanobody therapeutics, leveraging proprietary immunized nanobody libraries for high-throughput screening and in vitro/in vivo systems to develop multi-valent, multi-specific nanobodies.
The newly raised capital will be instrumental in accelerating Shaperon's research and development efforts. This investment is expected to support the progression of its existing clinical programs and further explore the potential of its unique therapeutic platforms. The funding underscores investor confidence in Shaperon's differentiated approach to tackling inflammatory and other complex diseases.
Shaperon plans to strategically deploy these funds to expand its pipeline and strengthen its position in the biotech sector. The company is focused on advancing its innovative therapies through clinical trials, aiming to bring new treatment options to patients with significant unmet medical needs and drive sustained growth.
